Preparation method of hydrogel with tissue repair and fiber prevention functions and hydrogel thereof

By using hydrogels with recombinant human collagen, methacrylylated chitosan and astragalus polysaccharide, the problem of endometrial damage and poor repair of uterine adhesions is solved, and efficient tissue repair and fibrosis are achieved Prevention, suitable for repair of damage to endometrium and uterine adhesions.

CN118718128BActive Publication Date: 2024-11-15NAT HEALTH COMMISSION INST OF SCI & TECH
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411232000.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-11-15
Estimated Expiration
2044-09-04

AI Technical Summary

Technical Problem

The prior art has limited repair effects when treating endometrial injury and uterine adhesions, especially the high adhesion rate after severe injury, and stem cell therapy is difficult to apply on a large scale, which limits clinical applications.

Method used

Hydrogels using recombinant human type I and III collagen, methacrylylated chitosan and astragalus polysaccharides are activated by photoinitiator to form gels for tissue repair and prevent fibrosis, suitable for intrauterine Repair of damage to membrane and uterine adhesions.

Benefits of technology

It achieves efficient endometrial repair and fibrosis prevention, significantly reduces the adhesion rate after severe injury, promotes tissue regeneration and cell migration, and is suitable for damage repair with irregular wounds.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118718128B_ABST
    Figure CN118718128B_ABST
Patent Text Reader

Abstract

The present invention provides a preparation method of a hydrogel with tissue repair and fibrosis prevention functions and the hydrogel thereof, wherein the hydrogel comprises a solution of recombinant human type I collagen, recombinant human type III collagen, or a mixture of recombinant human type I collagen and recombinant human type III collagen, methacryloyl chitosan containing a photoinitiator, and astragalus polysaccharide. When the solution is applied to the corresponding tissue, the tissue is irradiated externally with ultraviolet light or visible blue light, and the irradiation is stopped after the solution becomes a gel state, so as to prepare the hydrogel; the mass volume concentration of the astragalus polysaccharide is not more than 0.9%. The present invention proposes a gel with tissue repair and fibrosis prevention at the damaged part, which can be injected into the corresponding tissue in its liquid state, and can be photocrosslinked and cured to form a gel state under the irradiation of ultraviolet light or visible light, and is suitable for a variety of tissue repairs, antibacterial and prevention of fibrosis at the damaged part.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of materials, and in particular to a preparation method of a hydrogel with tissue repair and fiber prevention functions and the hydrogel. Background Art

[0002] The endometrium is an important component of the uterus, providing the necessary internal environment for embryo implantation and pregnancy maintenance. Uterine cavity manipulation, inflammation and infection are the main causes of severe endometrial damage and intrauterine adhesion (IAA), which may lead to amenorrhea, infertility, miscarriage, etc. During the occurrence of IUA, the damage to the basement membrane is usually irreversible and accompanied by fibrosis, manifesting as Asherman syndrome, that is, only atrophic and inactive uterine glands and a small amount of stroma exist.

[0003] Intrauterine adhesion separation is the first choice for IUA treatment, but the re-adhesion rate after severe IUA can be as high as 62.5%. In addition to surgical treatment, solid barriers such as intrauterine devices often cause local inflammation, and simple semi-solid barriers such as hyaluronic acid hydrogels have limited repair effects. Drugs such as metformin and nitroglycerin can increase blood flow, but the effect is not ideal. In recent years, some people have used stem cell therapy to achieve satisfactory results in the treatment of IUA, which can effectively reduce endometrial fibrosis and repair damaged endometrium, but these stem cells are difficult to obtain in large quantities, which greatly limits their clinical application. Summary of the invention

[0004] In order to solve the above problems, the present invention provides a method for preparing a hydrogel with tissue repair and fiber prevention functions, wherein the hydrogel comprises the following solution: recombinant human type I collagen, recombinant human type III collagen, or a mixture of recombinant human type I collagen and recombinant human type III collagen, a solution of methacryloyl chitosan containing a photoinitiator and zinc ions; when the solution is subjected to a viscosity test at 37°C and a shear rate of 1 / s, the viscosity is 3000±3000*15% mPa·s to 15000±15000*15% mPa·s, preferably, the viscosity is 3000±3000*10% mPa·s to 15000±15000*10% mPa·s, and more preferably, the viscosity is 3000±3000*5% mPa·s to 15000±15000*5% mPa·s. mPa·s; the mass volume concentration of astragalus polysaccharide is not greater than 0.9%, that is, the mass of astragalus polysaccharide in 100 ml solution is not greater than 0.9 g.

[0005] Human collagen is divided into more than 28 types of collagen according to different tissue locations, physiological functions, and molecular structures. Among them, type I collagen and type III collagen are closely related to the skin damage repair process and repair quality. From the distribution point of view, type I collagen is mainly found in adult skin, tendons, and bone tissue; type III collagen is mainly found in infant skin or vascular endothelium and intestines. Type I and type III collagen in the human body maintain the normal tissue structure of the skin, constitute the extracellular matrix network structure, play a role in supporting organs and protecting the body, and are also related to cell attachment and cell migration. The balanced ratio of the two also determines the hardness and tenderness of the skin, as well as the degree of wound healing and scarring. Therefore, when recombinant human collagen is used in tissue repair, both type I and type III collagen can effectively promote repair and tissue regeneration.

[0006] In one embodiment, the mass volume concentration of astragalus polysaccharide is 0.6% to 0.9%.

[0007] In one embodiment, the photoinitiator is lithium phenyl-2,4,6-trimethylbenzoyl phosphite or (2-hydroxy-2-methyl-1-[4-(2-hydroxyethoxy)phenyl]-1-propanone).

[0008] In one embodiment, when the viscosity of the hydrogel is tested at 37° C. and a shear rate of 1 / s, the viscosity is 10025.85 mPa·s to 3163.85 mPa·s.

[0009] In one embodiment, when the mass volume concentration of the methacryloylated chitosan is 8%, that is, 100 ml of the solution includes 8 g of methacryloylated chitosan, and when the mass volume concentration of recombinant human type I collagen, recombinant human type III collagen, or a mixture of recombinant human type I collagen and recombinant human type III collagen is 30%, that is, 100 ml of the solution includes 40 g of recombinant human type I collagen, recombinant human type III collagen, or a mixture of recombinant human type I collagen and recombinant human type III collagen, the volume ratio of the methacryloylated chitosan and the recombinant human type I collagen, recombinant human type III collagen, or the mixture of recombinant human type I collagen and recombinant human type III collagen is 3:1-1:1.

[0010] In one embodiment, the volume ratio of the methacryloylated chitosan to the recombinant human type I collagen, recombinant human type III collagen, or a mixture of recombinant human type I collagen and recombinant human type III collagen is 1:1, and the mass volume concentration of astragalus polysaccharide is 0.9%.

[0011] In one embodiment, a hydrogel for preventing and treating endometrial damage is provided, wherein the hydrogel is prepared by the above method.

[0012] In one embodiment, a hydrogel for preventing and treating intrauterine adhesions and thin endometrium is provided, wherein the hydrogel is prepared by the above method.

[0013] In one embodiment, a hydrogel for preventing and treating intrauterine adhesions and thin endometrium is provided, wherein the hydrogel comprises a solution of recombinant human type I collagen, recombinant human type III collagen, or a mixture of recombinant human type I collagen and recombinant human type III collagen, methacryloyl chitosan containing a photoinitiator, and astragalus polysaccharide. When the solution is applied to the corresponding tissue, ultraviolet light or visible blue light is externally irradiated to the damaged filling site, and the irradiation is stopped after the filled solution becomes a gel, thereby preparing the hydrogel; when the solution is subjected to a viscosity test at 37° C. and a shear rate of 1 / s, the viscosity is 3000±3000*15% mPa·s to 15000±15000*15% mPa·s; the mass volume concentration of astragalus polysaccharide is not greater than 0.9%, that is, the mass of astragalus polysaccharide in 100 ml of solution is not greater than 0.9 g.

[0014] In one embodiment, when the mass volume concentration of the methacryloylated chitosan is 8%, when the mass volume concentration of recombinant human type I collagen, recombinant human type III collagen, or a mixture of recombinant human type I collagen and recombinant human type III collagen is 30%, the volume ratio of the methacryloylated chitosan and the recombinant human type I collagen, recombinant human type III collagen, or a mixture of recombinant human type I collagen and recombinant human type III collagen is 1:1, and the mass volume concentration of astragalus polysaccharide is 0.9%.

[0015] When using the methacrylylated chitosan-collagen + astragalus polysaccharide hydrogel precursor solution for injury repair, the solution is first injected into the corresponding tissue, and then irradiated externally with ultraviolet light or blue light until the solution becomes gel-like and then stopped. At this time, the repair material is highly attached to the damaged tissue in a gel-like state to prevent tissue adhesion; at the same time, the repair effect of various components can be better exerted to promote the repair and regeneration of damaged tissue.

[0016] The material and application method are suitable for repairing various types of wounds, especially wounds of irregular shapes, such as epidermal damage, endometrial damage, cartilage regeneration, vaginal mucosal damage, etc., and can prevent fibrosis at the injured site. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments recorded in the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0018] Figure 1 The results of the hydrogel of the present invention on the cell migration of human endometrial stromal cells;

[0019] Figure 2 This is a diagram showing the repair effect of the hydrogel of the present invention on endometrial damage in rats.

[0020] In order to enable those skilled in the art to better understand the technical solutions in the present application, the present invention will be further described below in conjunction with the following embodiments. Obviously, the described embodiments are only part of the embodiments of the present application, rather than all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in the field without creative work should belong to the scope of protection of the present application. The present invention will be further described below in conjunction with the accompanying drawings and embodiments. DETAILED DESCRIPTION

[0021] Example 1. Preparation of raw materials of the present invention

[0022] 1. Preparation of methacryloyl chitosan (CSMA)

[0023] Chitosan powder was added to 0.1mol / L acetic acid solution with a mass volume fraction of 0.5%–5%, and stirred at room temperature until completely dissolved. The chitosan solution was placed in a 60°C water bath, and methacrylic anhydride was added dropwise, wherein the weight ratio of chitosan to methacrylic anhydride was 1:2-1:3. After the addition was completed, the reaction was stirred at 60°C for 6-12 hours. After the reaction was completed, 0.5mol / L NaOH solution was slowly added dropwise to the reaction solution to adjust the pH of the reaction solution to neutral. The neutral reactant solution was dialyzed in deionized water for 72 hours, and the water was changed every 6 hours. The dialyzed solution was frozen at -80°C and vacuum freeze-dried for 72 hours, and the freeze-dried powder product obtained was methacrylylated chitosan.

[0024] 2. Preparation of recombinant human type I collagen, recombinant human type III collagen, or a mixture of recombinant human type I collagen and recombinant human type III collagen (RC) solution

[0025] Dissolve the powder of recombinant human type I collagen, recombinant human type III collagen, or a mixture of recombinant human type I collagen and recombinant human type III collagen in PBS buffer and stir at 37°C until completely dissolved.

[0026] 3. Preparation of Astragalus Polysaccharide (APS) Solution

[0027] Dissolve the Astragalus polysaccharide powder in physiological saline and stir at room temperature until it is completely dissolved.

[0028] 4. Preparation of Methacrylylated Chitosan-Collagen+Astragalus Polysaccharide Hydrogel Precursor Solution

[0029] Take methacryloyl chitosan powder, dissolve it in PBS buffer, add 0.25% photoinitiator, and stir at room temperature for 12 h until it is completely dissolved. Then add collagen solution and Panax notoginseng total saponin solution, and stir at 4 °C in the dark. Among them, the mass volume concentration of methacryloyl chitosan is 8% (w / v), the mass volume concentration of collagen is 30% (w / v), and the mass volume concentration of astragalus polysaccharide solution is 30% (w / v).

[0030] 5. Hydrogel Preparation Method

[0031] When the methacrylylated chitosan-collagen + astragalus polysaccharide hydrogel precursor solution is applied for injury repair, the solution is first applied to the corresponding tissue site, and then the corresponding tissue site is irradiated externally with ultraviolet light (365 nm) or visible blue light (405 nm), and the solution is stopped after it becomes a gel. At this time, the hydrogel is highly attached to the damaged tissue in a gel state to prevent tissue adhesion; at the same time, the repair effect of various components can be better exerted to promote the repair and regeneration of damaged tissue. The material and application method are suitable for the repair of various wounds, especially irregularly shaped wounds, such as epidermal damage, endometrial damage, cartilage regeneration, vaginal mucosal damage, etc., and can prevent fibrosis of the damaged site. The mixed solution can quickly change from liquid to gel under the irradiation of ultraviolet light (365 nm) or visible blue light (405 nm).

[0032] Example 2. Viscosity test of methacrylylated chitosan-collagen solution at different volume ratios

[0033] Methacryloyl chitosan (CSMA)-collagen (RC) solutions with different volume ratios were dripped onto the sample stage of the rheometer, and the viscosity was tested at 37°C and a shear rate of 1 / s.

[0034] Table 1 Viscosity of CSMA:RC solutions with different ratios

[0035]

[0036] Viscosity test data show that changing the volume ratio of methacryloyl chitosan-collagen will directly affect the viscosity of the solution. When the ratio of CSMA:RC is greater than 3:1, the viscosity is lower than 3000 mPa·s, and its viscosity is small and fluidity is strong, which is not conducive to staying in the uterine cavity; when the ratio of CSMA:RC is less than 1:1, the viscosity is higher than 15000 mPa·s, and its viscosity is too high to achieve injectable type, and it is difficult to completely cover the damaged tissue and achieve the therapeutic effect. Therefore, it is believed that when CSMA:RC=1:1~3, the solution viscosity is suitable for use as a drug delivery platform in subsequent experiments.

[0037] Example 3 Experiment on the blood compatibility of composite hydrogels loaded with different proportions of astragalus polysaccharides

[0038] In the methacryloyl chitosan-collagen hydrogel precursor solution with a volume ratio of CSMA:RC=1:1, several different proportions of astragalus polysaccharide solutions were loaded to form several different proportions of methacryloyl chitosan-collagen + astragalus polysaccharide hydrogel precursor solutions. The loading ratios of the astragalus polysaccharide solution with a mass volume concentration of 30% were 1%, 2%, 3%, 4%, and 5%, that is, the total 100 ml of the solution contained 1 ml, 2 ml, 3 ml, 4 ml and 5 ml of the astragalus polysaccharide solution with a mass volume concentration of 30%.

[0039] Each group of precursor solutions was injected into a six-well plate, and after UV irradiation sterilization for 30 min, methacryloyl chitosan-collagen + astragalus polysaccharide hydrogels (respectively recorded as 1% hydrogel, 2% hydrogel, 3% hydrogel, 4% hydrogel, and 5% hydrogel) were formed. Whole blood from rats was collected using a sodium citrate anticoagulation blood collection tube and diluted 5 times with PBS solution. The diluted blood was centrifuged (2500 g, 15 min), and after complete stratification, the lower layer of red blood cells was taken and placed in an EP tube. PBS buffer was continuously injected into the EP tube, and the injection and aspiration were repeated until a colorless clear liquid was visible floating on the surface. The surface clear liquid was taken and diluted 10 times with PBS solution to obtain a red blood cell suspension (RBCs) for standby use. 100 μL of each group of hydrogels was injected into the bottom of a 2 mL plastic EP tube, and 1 mL of RBCs was injected into the surface of each group of hydrogels. At the same time, a positive control group was set up to take 0.1 mL of RBCs and 0.9 mL of 0.1% Triton-X and mix them in a 2 mL EP tube, and a negative control tube was set up to inject only 1 mL of RBCs. Each group was incubated in a 37 °C oven for 50-60 min, and each group of EP tubes was centrifuged at a centrifugal force of 2500 g for 15 min. After obvious stratification, 400 μL of the upper layer was taken in a 48-well plate, and the detection wavelength was set to λ=540 nm, and the OD value of each well was detected. The hemolysis rate of each group of hydrogels was calculated by the formula, and each group of experiments was repeated three times.

[0040] Hemolysis ratio (%) = (ODsample− ODnegative) / (ODpostive− ODnegative)×100

[0041] Table 2 Hemolysis rate of hydrogels with different astragalus polysaccharide loading ratios

[0042]

[0043] From the hemolysis rate data, we can see that the average hemolysis rates of the 4% hydrogel and 5% hydrogel groups are higher than 5% and gradually increase. Therefore, it is believed that when the astragalus polysaccharide loading rate is not higher than 3%, it has better blood safety for future animal applications.

[0044] Example 4 Effects of different concentrations of Astragalus polysaccharide on cell migration ability

[0045] In a methacryloyl chitosan-collagen hydrogel precursor solution with a volume ratio of CSMA:RC=1:1, several different proportions of astragalus polysaccharide solutions were loaded to form several different proportions of methacryloyl chitosan-collagen + astragalus polysaccharide hydrogel precursor solutions, and the loading ratio of the astragalus polysaccharide solution was 1%, 2%, and 3%.

[0046] Each group of precursor solutions was injected into a six-well plate, and after UV curing and sterilization for 30 min, methacrylylated chitosan-collagen + astragalus polysaccharide hydrogels (respectively denoted as 1% hydrogel, 2% hydrogel, and 3% hydrogel) were formed. Each group of hydrogels and DMEM low serum culture medium (DMEM basal medium, 3% fetal bovine serum and 1% double antibody, the double antibody is streptomycin and penicillin) were placed in a 50 ml sterile centrifuge tube to obtain a hydrogel concentration of 0.1 g / mL sample. The centrifuge tube containing the sample was placed in an incubator at 37 °C and 5% CO2 for 72 h to obtain a hydrogel extract. Draw horizontal lines every 0.5 cm on the back of the 6-well plate to evenly divide each well into three parts. Human endometrial stromal cells (HESCs) were placed at approximately 2×10 per well. 5 The cells were inoculated at a density of 100 μL in a 6-well plate and cultured in a 37°C, 5% CO2 incubator for 12 h. A 200 μL pipette tip was used to quickly scratch the dorsal horizontal line vertically, and the culture medium was discarded and rinsed three times with PBS buffer, and replaced with low-serum DMEM culture medium or low-serum extract. Two replicate wells were added to each group and continued to be cultured in a 37°C, 5% CO2 incubator. After 0 h and 24 h of culture, three areas were randomly selected using an inverted microscope for photography and quantification using Image J software, and the empty areas in the middle were recorded as A0 and A1, respectively. 12 The cell migration rate was calculated as follows:

[0047] Migration area (%) = (A0-A 12 ) / A0*100

[0048] Table 3 Cell migration rate at different astragalus polysaccharide loading ratios

[0049]

[0050] As can be seen from the table above, there is no significant difference in cell migration rate between the 1% hydrogel group and the control group, and there is no effect on cell migration, while the 2% hydrogel and 3% hydrogel groups are significantly different from the control group, and can significantly promote cell migration. Therefore, it is believed that when the astragalus polysaccharide loading ratio is greater than 2%, it can significantly promote cell migration and is beneficial to wound healing.

[0051] Example 5 Effects of hydrogels at different ratios on the repair ability and fibrosis degree of endometrial damage in rats

[0052] Methacryloyl chitosan-collagen hydrogel precursor solutions with volume ratios of CSMA:RC=1:1, CSMA:RC=2:1, and CSMA:RC=3:1 were prepared, and 3% astragalus polysaccharide was loaded in each solution to form several methacryloyl chitosan-collagen + astragalus polysaccharide hydrogel precursor solutions with different compositions, which were designated as CRA1, CRA2, and CRA3.

[0053] The rat endometrial injury repair experiment was established. Female SD rats aged 8 weeks, weighing about 250 g, and sexually mature were selected and cultured for one week. After the rats were anesthetized with isoflurane, the abdominal skin was prepared, the abdominal cavity was cut open, and the Y-shaped uterus was found. The upper and lower ends of the uterus were clamped with hemostatic clamps, and a 1 mL syringe was inserted into the rat uterus. 95% alcohol was injected until it was filled. After 60 seconds, the uterus was rinsed several times with normal saline. At this time, different concentrations of methacryloyl chitosan-collagen + astragalus polysaccharide hydrogel precursor solutions (CRA1, CRA2, CRA3) were injected into the injured uterus, and then irradiated externally with ultraviolet light or blue light for about 60 seconds, which showed that it was in a gel state. After suturing and disinfection, the rats were kept and observed. At the same time, an alcohol injury control group (referred to as Control) was set up. All rats were killed 7 days after surgery, and the uterine tissues were taken for photographs and fixed in 4% paraformaldehyde for 48 hours. After gradient dehydration with ethanol, paraffin embedding, and sliced ​​for Masson staining, they were observed.

[0054] like Figure 2As shown in the figure, the uterus of the alcohol-injured control group showed obvious congestion, while the uteri of the CRA1, CRA2, and CRA3 groups were uniform in thickness and free of congestion. There was a very small amount of material remaining in the uterus, which was in a gel-like state. From the statistical results of Masson staining and collagen deposition area, it can be seen that the uterine epithelium of rats injured by alcohol was lost, collagen deposition was more, and tissue fibrosis was severe. The uterine conditions of the CRA1, CRA2, and CRA3 groups were repaired to a certain extent, with increased endometrial thickness, increased number of stromal cells, and complete epithelial coverage of the uterine cavity. Among them, the number of glands in CRA1 and CRA3 was more (arrows in the figure). See Table 4. According to the statistical data, the collagen deposition area of ​​the CRA1 and CRA2 groups was improved to a certain extent. Overall, the repair and anti-fibrosis effects of the C1R1 group were more significant. The above results indicate that the C1R1 group, i.e., CSMA:RC=1:1, methacryloylated chitosan-collagen + astragalus polysaccharide hydrogel loaded with 2% astragalus polysaccharide, has the ability to promote the repair of endometrial damage, promote wound healing, and prevent tissue fibrosis.

[0055] Table 4 Average collagen deposition area ratio of rat endometrium repaired by hydrogels of different ratios

[0056]

[0057] It should be understood that the disclosed invention is not limited only to the specific method, scheme and material of description, because these all can change.It should also be understood that the terminology used herein is only for the purpose of describing specific embodiment scheme, rather than being intended to limit the scope of the present invention, and the scope of the present invention is only limited to the appended claims.

[0058] Those skilled in the art will also recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are also intended to be encompassed by the appended claims.

Claims

1. A solution for preparing a hydrogel having tissue repair and fiber prevention functions, It is characterized in that The solution for preparing the hydrogel includes the following solution: recombinant human type I collagen, recombinant human type III collagen, or a mixture of recombinant human type I collagen and recombinant human type III collagen, a solution of methacryloyl chitosan containing a photoinitiator, and astragalus polysaccharide; when the solution is subjected to a viscosity test at 37°C and a shear rate of 1 / s, the viscosity is 3000mPa·s~15000mPa·s; the mass volume concentration of astragalus polysaccharide is 0.6%~0.9%.

2. The solution according to claim 1, It is characterized in that The photoinitiator is phenyl-2,4,6-trimethylbenzoyl lithium phosphite or 2-hydroxy-2-methyl-1-[4-(2-hydroxyethoxy)phenyl]-1-propanone.

3. The solution according to claim 1, It is characterized in that When the solution is tested for viscosity at 37° C. and a shear rate of 1 / s, the viscosity is 10025.85 mPa·s to 3163.85 mPa·s.

4. The solution according to claim 1, It is characterized in that When the mass volume concentration of the methacryloyl chitosan is 8%, that is, 100 ml of the solution includes 8 g of methacryloyl chitosan; when the mass volume concentration of recombinant human type I collagen, recombinant human type III collagen, or a mixture of recombinant human type I collagen and recombinant human type III collagen is 30%, that is, 100 ml of the solution includes 30 g of recombinant human type I collagen, recombinant human type III collagen, or a mixture of recombinant human type I collagen and recombinant human type III collagen, the volume ratio of the methacryloyl chitosan and the recombinant human type I collagen, recombinant human type III collagen, or the mixture of recombinant human type I collagen and recombinant human type III collagen is 3:1-1:

1.

5. The solution according to claim 4, It is characterized in that The volume ratio of the methacryloyl chitosan to the recombinant human type I collagen, the recombinant human type III collagen, or the mixture of the recombinant human type I collagen and the recombinant human type III collagen is 1:1, and the mass volume concentration of the astragalus polysaccharide is 0.9%.

6. A hydrogel for preventing and treating endometrial damage, It is characterized in that When the solution described in any one of claims 1 to 5 is applied to the corresponding tissue, ultraviolet light or visible blue light is used to irradiate the damaged filling area externally, and the filling is stopped after the solution becomes gel-like, thereby preparing the hydrogel.

7. A hydrogel for preventing and treating intrauterine adhesions and thin endometrium, It is characterized in that When the solution described in any one of claims 1 to 5 is applied to the corresponding tissue, ultraviolet light or visible blue light is used to irradiate the damaged filling area externally, and the filling is stopped after the solution becomes gel-like, thereby preparing the hydrogel.

8. A hydrogel for preventing and treating intrauterine adhesions and thin endometrium, It is characterized in that The solution for preparing the hydrogel includes recombinant human type I collagen, recombinant human type III collagen, or a mixture of recombinant human type I collagen and recombinant human type III collagen, methacryloyl chitosan containing a photoinitiator, and a solution of astragalus polysaccharide. When the solution is applied to the corresponding tissue, ultraviolet light or visible blue light is used to externally irradiate the damaged filling area, and the irradiation is stopped after the filled solution becomes a gel state to prepare the hydrogel; when the solution is tested for viscosity at 37°C and a shear rate of 1 / s, the viscosity is 3000 mPa·s ~ 15000 mPa·s; the mass volume concentration of astragalus polysaccharide is 0.6%~0.9%.

9. The hydrogel according to claim 8, It is characterized in that When the mass volume concentration of the methacryloylated chitosan is 8%, when the mass volume concentration of recombinant human type I collagen, recombinant human type III collagen, or a mixture of recombinant human type I collagen and recombinant human type III collagen is 30%, the volume ratio of the methacryloylated chitosan and the recombinant human type I collagen, recombinant human type III collagen, or a mixture of recombinant human type I collagen and recombinant human type III collagen is 1:1, and the mass volume concentration of astragalus polysaccharide is 0.9%.

Citation Information

Patent Citations

  • 3D printing hydrogel for treating or preventing intrauterine adhesion and preparation method of hydrogel

    CN113563607A

  • Chitosan recombinant humanized collagen gel as well as preparation method and application thereof

    CN116173291A

  • Preparation method of curcumin-loaded recombinant collagen hydrogel and application of curcumin-loaded recombinant collagen hydrogel in treatment of intrauterine adhesion

    CN116763724A

  • Hydrogel for cartilage repair and preparation method thereof

    CN117122739A

  • Recombinant humanized collagen gel with stable cell adhesion

    CN118203694A